1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
353.88%
Cash & equivalents growing 353.88% while Drug Manufacturers - Specialty & Generic shows decline of -8.24%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
-9.90%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
197.46%
Below half the Drug Manufacturers - Specialty & Generic median of -7.77% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
515.88%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
55.77%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 1.78%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-53.08%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
113.34%
Below half the Drug Manufacturers - Specialty & Generic median of -1.71%. Jim Chanos would question if the company faces working capital strain.
18.19%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 11.04%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-0.38%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
3.16%
Intangibles growth < half the Drug Manufacturers - Specialty & Generic median of -0.26%. Joel Greenblatt sees fewer intangible expansions vs. peers. Possibly less impairment risk.
0.69%
Below half of Drug Manufacturers - Specialty & Generic median of -0.14%. Joel Greenblatt sees relatively minimal intangible expansions vs. peers.
69.12%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-0.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
7.09%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 3.72%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
22.83%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.56%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
10.68%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 1.69%. Jim Chanos might see a warning sign of stressed supplier payments.
42.03%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-5.92%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-20.18%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
264.63%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
24.38%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects potential working capital strain.
82.25%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
-100.00%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential shortage of multi-year commitments.
-2.27%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
13.35%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 2.23%. Jim Chanos suspects a red flag in ballooning future obligations.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects hidden or rapidly growing miscellaneous liabilities.
16.79%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 2.63%. Jim Chanos suspects an alarming rise in overall leverage.
22.15%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
76.64%
Below half Drug Manufacturers - Specialty & Generic median of -1.16%. Jim Chanos suspects poor profitability or large dividend drains.
0.71%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
29.53%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
22.96%
Below half Drug Manufacturers - Specialty & Generic median of -0.05%. Jim Chanos suspects slower net worth growth or losses vs. peers.
22.83%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.53%. Joel Greenblatt sees more aggressive expansions than peers.
32.05%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
78.69%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-652.48%
Below half of Drug Manufacturers - Specialty & Generic median 9.17%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
